Bromocriptine

Generic Name: Bromocriptine

Brand Names: Cycloset, Parlodel

Drug Type: Small Molecule

Chemical Formula: C_₃₂H_₄₀BrN_₅O_₅

CAS Number: 25614-03-3

Unique Ingredient Identifier: 3A64E3G5ZO

Background: Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptin...

Indication: For the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodop...

Associated Conditions: Acromegaly, Hyperprolactinemia, Parkinson's Disease (PD), Type 2 Diabetes Mellitus, Neuroleptic malignant syndrome (NMS)

Associated Therapies: -

Clinical Trials

Bromocriptine in the Treatment of Peripartum Cardiomyopathy

Phase 3

Withdrawn

Conditions: Peripartum Cardiomyopathy

Interventions: Drug: Bromocriptine
Other: Guideline-driven medical therapy (GDMT)

First Posted Date: 2015-10-29

Last Posted Date: 2023-04-04

Lead Sponsor: Montreal Heart Institute

Registration Number: NCT02590601

Locations: 🇨🇦
Montreal Heart Institute, Monteal, Quebec, Canada

Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes

Phase 2

Completed

Conditions: Type 1 Diabetes

Interventions: Other: Placebo
Drug: Bromocriptine

First Posted Date: 2015-09-09

Last Posted Date: 2021-09-13

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 108

Registration Number: NCT02544321

Locations: 🇺🇸
University of Colorado-Denver, Anshutz Medical Campus, Aurora, Colorado, United States

Bromocriptine and Insulin Sensitivity

Not Applicable

Completed

Conditions: Insulin Sensitivity

Interventions: Drug: Bromocriptine

First Posted Date: 2015-04-29

Last Posted Date: 2016-05-24

Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Target Recruit Count: 15

Registration Number: NCT02428946

Locations: 🇳🇱
Academic Medical Center, Amsterdam, Netherlands

Dopaminergic Effects on Brown Adipose Tissue

Not Applicable

Completed

Conditions: Obesity

Interventions: Drug: Bromocriptine

First Posted Date: 2015-04-29

Last Posted Date: 2015-04-29

Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Target Recruit Count: 8

Registration Number: NCT02428933

Locations: 🇳🇱
Academic Medical Center, Amsterdam, Netherlands

Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy

Phase 4

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Cycloset

First Posted Date: 2014-11-24

Last Posted Date: 2019-06-21

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 23

Registration Number: NCT02299050

Locations: 🇺🇸
University of Texas Health Science Center, San Antonio, Texas, United States

Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease

Phase 3

Completed

Conditions: Parkinson Disease

Interventions: Drug: Pramipexole
Drug: Placebo pramipexole
Drug: Bromocriptine
Drug: Placebo bromocriptine

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 315

Registration Number: NCT02172573

Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study

Phase 3

Conditions: Insulin Resistance
PCOS

Interventions: Drug: Bromocriptine

First Posted Date: 2014-05-08

Last Posted Date: 2014-05-08

Lead Sponsor: IWK Health Centre

Target Recruit Count: 60

Registration Number: NCT02133755

Locations: 🇨🇦
IWK Health Centre, Halifax, Nova Scotia, Canada

Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment

Not Applicable

Terminated

Conditions: Graves Ophthalmopathy

Interventions: Drug: Bromocriptine
Drug: Methimazole
Drug: Pentoxifylline

First Posted Date: 2013-07-09

Last Posted Date: 2013-07-09

Lead Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Target Recruit Count: 31

Registration Number: NCT01893450

Locations: 🇲🇽
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

Phase 4

Completed

Conditions: Parkinson's Disease

Interventions: Drug: pramipexole
Drug: Bromocriptine

First Posted Date: 2012-08-28

Last Posted Date: 2017-09-15

Lead Sponsor: Sandoz

Target Recruit Count: 121

Registration Number: NCT01673724

Locations: 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of

and more 4 locations

Effect of Bromocriptine on Left Ventricular Function in Women With Peripartum Cardiomyopathy

Phase 2

Completed

Conditions: Peripartum Cardiomyopathy

Interventions: Drug: Bromocriptine

First Posted Date: 2009-10-20

Last Posted Date: 2020-09-07

Lead Sponsor: Hannover Medical School

Target Recruit Count: 64

Registration Number: NCT00998556

Locations: 🇩🇪
Hannover Medical School (MHH), Hannover, Niedersachsen, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy